Categories: DiagnosticsDNANews

BillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025

MENLO PARK, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) — BillionToOne, Inc. (NASDAQ: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for third quarter ended September 30, 2025 after the market close on Tuesday, December 9, 2025. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

To participate in the conference call, please register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast will be available on the “Events” page of BillionToOne’s investor relations website at https://investors.billiontoone.com/.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company’s patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.

Investor Contact
ir@billiontoone.com

Media Contact
billiontoone@moxiegrouppr.com

Staff

Recent Posts

Atropos Health Expands Oncology Precision Medicine Capabilities with Publication of New AI Algorithms for Rare Disease and Integration of ASCO Guidelines

Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform…

57 minutes ago

USF and Old Dominion to Play in the 2025 StaffDNA Cure Bowl

PLANO, Texas, Dec. 5, 2025 /PRNewswire/ -- Teams playing in the StaffDNA® Cure Bowl were…

1 hour ago

The Dot Corp Expands Services With New Promotional Products & Apparel Division

IRVINE, Calif., Dec. 5, 2025 /PRNewswire/ -- The Dot Corp has expanded its services with…

1 hour ago

Vaniam Group Launches Predictive Pathways: A New Capability for Anticipating Market-Shaping Signals

CHICAGO, Dec. 5, 2025 /PRNewswire/ -- Vaniam Group™, a category leader redefining medical communications, announced…

1 hour ago

Biorep Technologies Announces First Successful Independent Research Use of the PRISM System in Islet Isolation

Results confirm reproducibility and research readiness for islet isolation of Biorep's next generation laboratory platform.MIAMI,…

1 hour ago